Mirati Therapeutics, Inc. (MRTX): Price and Financial Metrics


Mirati Therapeutics, Inc. (MRTX): $58.02

-0.78 (-1.33%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add MRTX to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

MRTX POWR Grades


  • Value is the dimension where MRTX ranks best; there it ranks ahead of 44.9% of US stocks.
  • The strongest trend for MRTX is in Stability, which has been heading down over the past 179 days.
  • MRTX's current lowest rank is in the Momentum metric (where it is better than 4.64% of US stocks).

MRTX Stock Summary

  • Of note is the ratio of Mirati Therapeutics Inc's sales and general administrative expense to its total operating expenses; merely 8.55% of US stocks have a lower such ratio.
  • MRTX's price/sales ratio is 65.24; that's higher than the P/S ratio of 96.8% of US stocks.
  • As for revenue growth, note that MRTX's revenue has grown 438.08% over the past 12 months; that beats the revenue growth of 98.06% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Mirati Therapeutics Inc are MORF, NKTR, RCUS, AVIR, and CCCC.
  • Visit MRTX's SEC page to see the company's official filings. To visit the company's web site, go to www.mirati.com.

MRTX Valuation Summary

  • MRTX's price/sales ratio is 667.2; this is 17457.89% higher than that of the median Healthcare stock.
  • Over the past 99 months, MRTX's price/sales ratio has gone NA NA.
  • Over the past 99 months, MRTX's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for MRTX.

Stock Date P/S P/B P/E EV/EBIT
MRTX 2021-08-31 667.2 7.8 -17.9 -17.4
MRTX 2021-08-30 664.0 7.7 -17.8 -17.3
MRTX 2021-08-27 641.6 7.5 -17.2 -16.7
MRTX 2021-08-26 640.0 7.4 -17.1 -16.7
MRTX 2021-08-25 612.8 7.1 -16.4 -15.9
MRTX 2021-08-24 581.4 6.8 -15.6 -15.1

MRTX Growth Metrics

    Its year over year net income to common stockholders growth rate is now at -57.13%.
  • The 2 year net cashflow from operations growth rate now stands at -216.5%.
  • Its 3 year net cashflow from operations growth rate is now at -66.92%.
Over the past 52 months, MRTX's revenue has gone up $72,092,000.

The table below shows MRTX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 72.092 -388.8 -581.784
2021-09-30 73.501 -327.236 -483.251
2021-06-30 13.132 -356.967 -490.533
2021-03-31 13.132 -322.943 -406.962
2020-12-31 13.398 -271.531 -357.937
2020-09-30 12.217 -237.012 -329.226

MRTX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • MRTX has a Quality Grade of D, ranking ahead of 13.91% of graded US stocks.
  • MRTX's asset turnover comes in at 0.011 -- ranking 387th of 682 Pharmaceutical Products stocks.
  • CYRX, LUMO, and BDSI are the stocks whose asset turnover ratios are most correlated with MRTX.

The table below shows MRTX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.011 1 -0.668
2021-03-31 0.013 1 -0.658
2020-12-31 0.015 1 -0.750
2020-09-30 0.020 1 -0.781
2020-06-30 0.003 1 -0.737
2020-03-31 0.004 1 -0.765

MRTX Price Target

For more insight on analysts targets of MRTX, see our MRTX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $216.18 Average Broker Recommendation 1.56 (Moderate Buy)

MRTX Stock Price Chart Interactive Chart >

Price chart for MRTX

MRTX Price/Volume Stats

Current price $58.02 52-week high $195.99
Prev. close $58.80 52-week low $51.16
Day low $56.37 Volume 716,233
Day high $60.76 Avg. volume 727,539
50-day MA $72.04 Dividend yield N/A
200-day MA $123.43 Market Cap 3.22B

Mirati Therapeutics, Inc. (MRTX) Company Bio


Mirati Therapeutics develops molecularly targeted cancer treatments that are intended to inhibit tumor growth. The company was founded in 1995 and is based in San Diego, California.


MRTX Latest News Stream


Event/Time News Detail
Loading, please wait...

MRTX Latest Social Stream


Loading social stream, please wait...

View Full MRTX Social Stream

Latest MRTX News From Around the Web

Below are the latest news stories about Mirati Therapeutics Inc that investors may wish to consider to help them evaluate MRTX as an investment opportunity.

Is a Surprise Coming for Mirati (MRTX) This Earnings Season?

Mirati (MRTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Yahoo | February 25, 2022

5 Drug/Biotech Stocks Set to Outpace Q4 Earnings Estimates

Let us take a look at some drug/biotech stocks, EVLO, GMDA, APLS, MRTX and ITOS, which are poised to beat on fourth-quarter earnings.

Yahoo | February 24, 2022

Mirati (MRTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Mirati (MRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | February 21, 2022

Mirati (MRTX) Down on Longer Review Period for Adagrasib NDA

The FDA accepts Mirati's (MRTX) NDA for its lung cancer candidate, adagrasib. A decision is expected by Dec 14, 2022.

Yahoo | February 17, 2022

JonesTrading Thinks Mirati Therapeutics’ Stock is Going to Recover

JonesTrading analyst Soumit Roy reiterated a Buy rating on Mirati Therapeutics (MRTX – Research Report) today and set a price target of $165.00. The company's shares closed last Tuesday at $107.39, close to its 52-week low of $98.55. According to TipRanks.com, Roy is a 4-star analyst with an average return of 12.9% and a 32.9% success rate. Roy covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Monopar Therapeutics Inc, and Actinium Pharmaceuticals. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Mirati Therapeutics with a $168.20 average price target, implying a 63.4% upside from current levels.

Catie Powers on TipRanks | February 16, 2022

Read More 'MRTX' Stories Here

MRTX Price Returns

1-mo -17.75%
3-mo -34.09%
6-mo -57.58%
1-year -61.19%
3-year -24.39%
5-year 1,685.23%
YTD -60.45%
2021 -33.21%
2020 70.45%
2019 203.77%
2018 132.44%
2017 284.21%

Continue Researching MRTX

Want to see what other sources are saying about Mirati Therapeutics Inc's financials and stock price? Try the links below:

Mirati Therapeutics Inc (MRTX) Stock Price | Nasdaq
Mirati Therapeutics Inc (MRTX) Stock Quote, History and News - Yahoo Finance
Mirati Therapeutics Inc (MRTX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6078 seconds.